Ovid Therapeutics (stock symbol: OVID) Logo in transparent PNG format

Ovid Therapeutics Logo large

Ovid Therapeutics Logo icon format

Ovid Therapeutics Logo large for dark backgrounds

Ovid Therapeutics Logo icon format for dark backgrounds

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

  • Website domain: ovidrx.com
  • Employees: 44
  • Marketcap: $0.13 Billion USD

Page last updated on:

August 7th, 2022

Categories: